Category Archives: Regenerative Medicine

The PAINWeek National Conference, September 6-9

MONTCLAIR, N.J. (PRWEB) August 11, 2022

The statistics are alarming: At least a fifth of the US population has chronic pain.[1] Costs to society, ranging from direct costs to lost work, is over $630 billion a year.[2] Something needs to change, and education will help. At the PAINWeek National Conference, September 6-9 at The Cosmopolitan of Las Vegas, attendees will experience stellar pain management education, including the ASIPPAmerican Society of Interventional Pain Physiciansand the Interventional Pain Management Tracks.

The ASIPP Track will include Nick Knezevic, MD, PhD, presenting Atomic Secrets: Regenerative Medicine in Managing Chronic Pain. He commented, ASIPP has a long-standing relationship with PAINWeek. Together, theyve organized a series of lectures with ASIPP key leaders as speakers to help explain the importance of interventional pain management procedures in managing pain conditions.

The ASIPP Track will also feature the following courses and presenters:

Sean Li, MD, who will present during the Interventional Pain Management Track, stated, PAINWeek has always been one of my favorite meetings because of its diversity and inclusion: it is the only meeting where I can join clinicians from all specialties who treat pain patients. Dr. Li's sessions: The Petrified Forest: Sacroiliac Joint Dysfunction and Treatment Update; and When Stars Align: The New Era of Peripheral Nerve Stimulation. He continued, Attendees will experience an emersion of emotional and intellectual experiences into the world of pain management. Dont miss out!

Johnathan Goree, MD, who will co-present East v. West: Who Should Hold the Needle First?, commented, I am excited to again take part in PAINWeek, this time discussing back pain and Whats next? I will debate Carrie Hyde, MD, a physician medical acupuncturist, and discuss our approaches to the low back pain patient, treatment philosophies, cost benefit analysis. Wholl win the debate? Both attendees and patients!

The Interventional Pain Management Track will also feature:

PAINWeek will present over 75 CME/CE credit hours in tracks such as Behavioral Pain Management, Chronic Pain Syndromes, Health Coaching, Integrative Pain Management, Medical/Legal, Neurology, Physical Therapy, Pharmacotherapy, and Psychedelics. Master Classes, Special Interest Sessions, and sponsored courses complement the agenda, along with tracks presented by the International Pelvic Pain Society.

For more information, click PAINWeek or go to painweek.org.

Dr. Goree: Associate Professor and Director of Chronic Pain Division, University of Arkansas for Medical Sciences, Little Rock. Dr. Knezevic: Clinical Professor of Anesthesiology & Surgery, College of Medicine, University of Illinois, Chicago. Dr. Li: Regional Medical Director, National Spine and Pain Centers, Lincroft, New Jersey.

PAINWeek accreditation provided by Global Education Group:

Global Education Group focuses on producing partnership-based CME for healthcare practitioners. The Global team works with a select group of medical education companies, associations, academic institutions, and healthcare facilities to develop and accredit live healthcare conferences and workshops as well as online activities. With each partnership or joint providership, Global brings accreditation expertise, project management excellence and grant funding intelligence. Based in Littleton, Colo., Global has accreditation with commendation from the ACCME and accredited with distinction from the ANCC. Global also holds accreditations to offer continuing education for nurse practitioners, pharmacists, dietitians, dentists, and psychologists. Global is a division of Ultimate Medical Academy.

1. National Center for Health Statistics, National Health Interview Survey, 2019.2. https://nationalpain.org/fast-facts-about-pain

###

Share article on social media or email:

Read this article:
PAINWeek 2022 Announces the Return of the ASIPP and Interventional Pain Management Tracks - PR Web

Minoxidil, or the active ingredient in Rogaine, has been billed as a miracle cure for hair loss. But what is it, really? And more importantly, who does it help? Hair thinning can be a painful process so we take special notice when we find something that can stop or reverse it. While weve tried the natural route (hello, rosemary oil) its not every day we find an actually clinically proven solution to hair loss. So, to learn more about this ingredient, we checked in with an expert for a guide on what it is, its side effects, benefits, and how to use it.

About the Expert

Azza Halim, M.D., is a board-certified aesthetic medicine, anti-aging, and regenerative medicine physician.

Minoxidil was originally developed to lower blood pressure in the 1960s, with a happy side effect being hair growth. It was then formulated into a topical treatment to treat hair loss in men as Rogaine, followed by a female-specific product. Board-certified physician Azza Halim, M.D. explains, It is a vasodilator medicationthat canbe taken as a pill or applied topically. This means it expandsbloodvesselsto increase flow, circulation, and add nutrients to the follicles, she continues.

The main benefit of minoxidil is restoring haireven a little bit back can be a huge confidence booster. According to Dr. Halim, minoxidil may expand the hair follicles, especially those that shrunk over time or in response to hormonal changes, which translates to more sustained growth. It also prolongs the growth phase of the hair cycle, aka the anagen phase, she notes. Minoxidil can increase hair thickness, density, and treat hair disorders like androgenetic alopecia and female pattern hair loss.

Ideal candidates are those in early stages of hair loss or thinning, says Dr. Halim. All hair types can take minoxidil, though it may be less effective on women with natural hair who have scarring from alopecia. Pregnant women cant take minoxidil, and it isnt safe for nursing mothers either. It can cause irritation when mixed with hair dye, though it can be used on color-treated hair.

As with everything there are pros and cons/side effects, Dr. Halim tells us. Side effects include scalp dryness, irritation, low blood pressure, allergic reaction, and rarelybut it is possibleto trigger interim hair loss before stimulating hair growth. Other side effects include unwanted hair growth, lightheadedness, and scalp irritation.

Minoxidil must be applied topically twice a day, says Dr. Halim. Dont expect instant gratification, however, as results take three to four months. If you stop minoxidil, be warned that hair will revert to the thickness it would have been if you didnt take it at all, not where it was when you startedthis can be a shocker. The downside is once discontinued, hair then reverts to baseline and new growth will be lost within few months, therefore, it needs maintained use, she continues. Minoxidil giveth and minoxidil taketh away.

This 2% solution is clinically proven to help fight hair loss by activating hair follicles at the scalp and extending your hairs natural growth cycle. You can even subscribe to get this product delivered to your door every month so you wont miss out on a treatment.

With a 4.2 star review from nearly 200 reviews on Ulta, its no wonder this treatment is recommended by so many. Yes, it does take about three to six months for results to show, but once they do, youll realize why it was worth the wait.

A 5% topical treatment, Rogaines four-month supply will take you to the first stages of hair regrowth.

Promote hair growth with minoxidil and refresh follicles naturally with biotin, thanks to this hair growth oil. Youll be happy to know its free of parabens, gluten, sulfates, and any other nasty ingredients that may irritate your scalp. Translation? You likely wont experience any minoxidil side effects.

Minoxidil meets DHT blocker Finasteride and Spironolactone, which slows the production of hair loss-causing hormones. People who have used this treatment have said they noticed hair regrowth in as little as one month.

Original post:
What Is Minoxidil? A Complete Guide to the Product - Mane Addicts

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced the appointment of Dr. Gail K. Naughton to its Board of Directors.

Dr. Naughton has been a pioneer in the field of regenerative medicine for over 35 years. She was the founder of Advanced Tissue Sciences (NASDAQ:ATIS) where she oversaw the design and development of the worlds first up-scaled manufacturing facility for cell-based products, established corporate development and marketing partnerships with companies including Smith & Nephew, Medtronic, and Inamed Corporation, was pivotal in raising over $350 million from the public market and corporate partnerships, and brought four human cell-based products from concept through FDA approval and market launch. She founded Histogen (NASDAQ:HSTO) in 2007 and holds more than 125 U.S. and foreign patents and has been extensively published in the field. Dr. Naughton served as Dean of the College of Business Administration at San Diego State University from 2002 until 2011 where she helped to make SDSU the first US campus to establish a Ph.D./MBA in life sciences. In 2000, Dr. Naughton received the 27th Annual National Inventor of the Year award by the Intellectual Property Owners Association in honor of her pioneering work in the field of tissue engineering and regenerative medicine. Dr. Naughton received her Ph.D. and M.S. from NYU Medical Center and an MBA from UCLA. She currently sits on the Board of directors of Therapeutics MD (NASDAQ: TXMD) and is the Chair of the Board of the La Jolla Institute for Immunology.

A highly accomplished visionary in biotechnology, Dr. Naughton has brought several FDA approved products to market, and we are very pleased to welcome her to our board. Her unparalleled expertise will be very helpful to CEL-SCI, stated CEL-SCI CEO Geert Kersten.

Dr. Naughton commented, Based on the results of the largest study of its kind, Multikine can significantly improve outcomes for patients with newly diagnosed head and neck cancer. CEL-SCIs management team and board have been tenacious in advancing an immune therapy that can have the greatest beneficial impact on patientswhen they are first diagnosed with cancer. I look forward to contributing my guidance as the company transitions through regulatory approval and into delivering treatments that can help extend patient lives.

About CEL-SCI Corporation

CEL-SCI believes that boosting a patients immune system while it is still intact should provide the greatest possible impact on survival. Therefore, in the Phase 3 study CEL-SCI treated patients who are newly diagnosed with advanced primary squamous cell carcinoma of the head and neck with the investigational product Multikine* first, BEFORE they received surgery and radiotherapy or surgery plus concurrent radiochemotherapy (the current standard of care for these patients). This approach is unique. Most other cancer immunotherapies are administered only after conventional therapies have been tried and/or failed. Multikine (Leukocyte Interleukin, Injection) received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck. CEL-SCI believes that this Phase 3 study is the largest Phase 3 study in the world for the treatment of advanced primary head and neck cancer.

Multikine is designed to help the immune system see the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. The Phase 3 study was started in early 2011 and was fully enrolled with 928 patients in September 2016. To prove an overall survival benefit, the study required CEL-SCI to wait until at least 298 (deaths) events had occurred among the two main comparator groups. The study results announced in June 2021 showed excellent survival benefit for those patients who received Multikine treatment regimen plus surgery and radiation. When chemotherapy was added to radiotherapy following surgery the survival benefit was negated.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such statements include, but are not limited to, statements about the terms, expected proceeds, use of proceeds and closing of the offering. Factors that could cause or contribute to such differences include an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2021. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.

More:
CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors - Business Wire

Wilmington, NC - (NewMediaWire) - August 3, 2022 - Chronic pain conditions can have severe adverse effects on the quality of one's life, from forcing them to contend with debilitating, life-altering, incessant pains to robbing them of their independence. Despite its significant advances in recent years, conventional medicine is yet to offer conclusive solutions for many such conditions, leaving many patients at a loss regarding their options. Luckily, the field of regenerative medicine, a specialty area of QC Kinetix (Wilmington), offers a better alternative to conventional medicine in combating many chronic pain conditions with evidence-based results. The pain control clinic offers patients a way out from aggravating pain and a good shot at regaining complete control of lost or limited body functions such as mobility.

A brainchild of years of painstaking research and innovative insight, the clinic's regenerative therapies take advantage of the human body's natural self-healing processes to restore and heal. Athletes who have suffered sports injuries and are looking for a way to get back in the game can rely on the clinic's sports medicine treatments to help. The treatment providers at QC Kinetix (Wilmington) use natural sports medicine treatments on their patients with renewed hope for a full recovery.

Before administering the sports medicine treatments, the medical providers begin each process with a complete diagnosis, extensive on-site medical examinations, and medical history deep-dives to establish each patient's suitability for regenerative treatment, including athletes. This initial step is crucial in helping identify individuals, such as cancer patients, for whom regenerative medicine is unsuitable and potentially harmful.

Upon passing QC Kinetix (Wilmington)'s mandatory pre-screening process, patients can begin their journey to wellness immediately. The clinic's medical providers develop individualized treatment plans to fast-track each patient's recovery process. They locally administer biologic agents directly to the affected body parts using minimally invasive procedures that, unlike surgeries, leave no wounds that take time to heal. These agents trigger, stimulate, and sustain a restorative immunity process that addresses underlying issues causing chronic pain instead of focusing on alleviating their symptoms.

Going by many patients' first-hand accounts about their experiences at QC Kinetix (Wilmington), regenerative therapies are effective against many chronic pain conditions. The treatments can be used for joint, hip, knee, elbow, shoulder, wrist, toe, heel, thigh, finger, and lower & upper back pain treatments. For back pain treatment in Wilmington, patients who have undergone the process using regenerative medicine have admitted realizing significant progress after their first few sessions, with some reporting full recovery in a few months. Rather than undergoing invasive surgeries, many patients have chosen the natural way of back pain treatment using regenerative medicine. The back pain treatment at the pain control clinic focuses on the point of injury or pain to accelerate the natural healing process, leading to long-lasting pain relief.

While analgesics can help alleviate pain, they are fleeting remedies at best since they focus on symptoms instead of treating their causes at the source. Therefore, patients who prefer this route can never stop using such medications without experiencing a resurgence of their pains. With prolonged usage comes many associated side effects with far-reaching health implications. In addition, they risk developing an unhealthy dependence on analgesics, a slippery slope to full-blown addiction. Luckily, with QC Kinetix (Wilmington) regenerative medicine, such individuals can begin weaning themselves off pain medications after the first few sessions.

Describing their experience at QC Kinetix (Wilmington), one impressed patient said, "I am a very anti-doctor person and, even though I was attended to by one, it has been a completely different atmosphere. I am on my third treatment, and after the first, I had much improvement in mobility and less pain. The second treatment was a little more intense than the first, but still no downtime and right back to work. After a couple of days, I can confirm full mobility and zero pain!"

Visit QC Kinetix (Wilmington) at 1410 Commonwealth Dr, Suite 100, Wilmington, NC, 28403, US, for a free consultation or to know more about their sports medicine and back pain treatment. Patients can learn more about their Wilmington office by visiting their website. Alternatively, they can contact one of their representatives via phone at (910) 378-9909 for queries.

Media Contact

QC Kinetix (Wilmington)

Scott Hoots

(910) 378-9909

1410 Commonwealth Dr, Suite 100

Wilmington

NC

28403

US

https://qckinetix.com/wilmington/

Continue reading here:
QC Kinetix (Wilmington) is the Go-to Regenerative Medicine Clinic for Back Pain and Sports Injury Treatment - Yahoo Finance

LAS VEGAS, NV, Aug. 01, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire Meso Numismatics, Inc. (Meso Numismatics or the Company) (MSSV), a technology company specializing in Biotech and Numismatics, is pleased to announce additional global expansion by opening stem cell therapy and regenerative medicine facilities in Indonesia. The new facilities emphasize Global Stem Cells Group's objective of introducing its therapies and technology to meet market demands in populous parts of the world.

In partnership with the Dr. Yanti Aesthetic Clinics, which currently has 6 branches across Indonesia, this latest GSCG expansion will promote high standards of service in regenerative medicine across the country. As part of this effort, through GSCG the International Society for Stem Cells Applications (ISSCA) has granted Dr. Yanti Aesthetic Clinics membership and use of its brand, products, therapies, and training on how to apply stem cell therapies.

This new partnership seeks to expand the Global Stem Cells Group (GSCG) brand and create centers of excellence in cell therapy to meet the high demand within the vast Asian markets, said David Christensen, CEO of MSSV. GSCG is rapidly expanding its global operations as it seeks to become a significant player in the lucrative regenerative medicine industry. To achieve our expansion plans, our organization is partnering with healthcare providers specializing in regenerative medicine with at least five years of experience in the healthcare sector.

Video: https://youtu.be/T2CFjsps9qk

The vision behind the effort.

The Indonesia addition is the latest part of an expanding medical network of partners, and it will formalize and strengthen ties, establishing a global center of excellence to guarantee that we effectively use the underlying basic stem cell technology for medical conditions, where traditional therapeutic approaches seem to have failed. This is consistent with GSCG's overall strategy for developing regenerative medicine through data-driven studies, disease modeling, and cell-based therapeutics.

The Dr. Yanti Aesthetic Clinic is a key partnership because it provides the organizational and physical infrastructure needed to disseminate need-based stem cell locally. And Global Stem Cells Group's outstanding cell and stem cell biology and disease pathophysiology give an edge to patients for which they are prescribed.

The opening in Indonesia also presents the perfect opportunity to translate breakthrough therapies from basic discoveries to useful products by drawing upon the skills and local knowledge promoted within Dr. Yanti Aesthetic Clinics.

GSCG group managing director, Benito Novas, provided a clear description of the new strategic direction and objectives. "Our goal is to make regenerative medicine benefits a reality for both doctors and patients all around the world. We recently launched a very similar effort in Pakistan. Additional announcements are planned in the near future as we attempt to expand our presence." Meso Numismatics and Global Stem Cells Group Expand its Global Footprint

The current market outlook.

Stem cell therapy is striving to become an increasingly effective clinical solution to treat conditions that traditional or mainstream medicine offers only within palliative care and pain management. Patients all over the world are searching for a natural regenerative alternative without the potential risks and side effects sometimes associated with mainstream pharmaceuticals. With the opening of each new treatment center in populous regions such as Indonesia, GSCG is working to help stem cell therapy and regenerative medicine to eventually move from alternative and elective procedures to mainstream protocols.

This new clinic effort will play a significant role in the development of regenerative medicine in Indonesia and indeed the rest of the world by adding yet another opportunity for continuous improvement through research and development, Christensen continued. By adding busy clinics in population centers, we plan to consistently generate high volumes of reliable clinical data to assist us with the development and refinement of even more medicines and treatments.

About Dr. Yanti Aesthetic Clinics

Dr. Yanti Aesthetic Clinics is a premier cosmetic and aesthetics clinic based in Kelapa Gading, Jakarta Utara. Since its inception in 2004 in Surabaya by Dr. Khoe Yanti Khusmiran, the clinic has expanded to over 6 branches throughout Indonesia. Dr. Yanti clinics provide a range of skin and body enhancement treatments through minimally invasive and non-invasive procedures the expertise of which are a natural fit for the addition of a variety of stem cell therapies.

"Indonesians have a growing need for the latest medical technology that is reliable, potent, has reduced side effects, and leverages the bodys own healing biochemistry to resolve injury and aging, said Dr. Yanti. We are honored to be a part of GSCG, which has a proven 10-year track record in the market with a strong and growing international reputation. This new partnership is expected to create a wide variety of custom treatment options we can offer our patients and treat injury and illness in ways we could not before.

The newly formed partnership will deliver revolutionary medicines through Dr. Yanti clinics to assist patients in avoiding permanent harm and live a healthier life, while changing the paradigm from asymptomatic treatments to cures that may improve and restore quality of life.

More about Global Stem Cells Group

GSCG delivers leadership in regenerative medicine research, patient applications, and training through our strategic global networks. We endeavor to enable physicians to treat otherwise incurable diseases using stem cell therapy and to improve the quality of life and care across the world.

For this reason, GSCG works with innovative, next-generation therapy providers like Dr. Yanti Aesthetic Clinics to give access to one-of-a-kind holistic and safe treatment options.

More information regarding this transaction and the Global Stem Cells Group may be found at GSCG.

This press release should be read in conjunction with all other filings on http://www.sec.gov

For more information on Global Stem Cells Group please visit: http://www.stemcellsgroup.com

About Meso Numismatics: Meso Numismatics, Corp is an emerging Biotechnology and numismatic technology company. The Company has quickly become the central hub for rare, exquisite, and valuable inventory for not only the Meso region, but for exceptional items from around the world.

Meso has now added Biotechnology to its portfolio and will continue to grow the company in this new direction. With the Company's breadth of business experience and technology team, the Company will continue to help companies grow.

Forward-Looking Statements

Some information in this document constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements, such as the closing of the share exchange agreement. The words plan, "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Meso Numismatics, Inc., herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Meso Numismatics, Inc. disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

For further information, please contact:investor.relations@mssvinc.com Telephone: (800) 956-3935

Read more:
Global Stem Cells Group Expands Its Stem Cell Therapy and Regenerative Medicine Centers to Indonesia - GlobeNewswire

Wilmington, Delaware, United States, Transparency Market Research Inc.: 3D cell culture is a controlled simulated environment outside of a living organism, wherein cells are allowed to grow and migrate by interacting within their habitat. 3D cell culture nurtures levels of cell differentiation and tissue organization which is not viable in traditional 2D culture systems. 3D cell culture has more tissue divergence and cell cohesion properties.

Read Report Overview - https://www.transparencymarketresearch.com/3d-cell-culture-market.html

3D cell structures are gaining popularity and have shown increased applications, especially in the early drug discovery and other research and development. This technique is used by researchers to fabricate physiologically similar cell culture stereotypes that aid drug discovery and development. Persistent need to refine efficiency in pharmaceutical research and development is also encouraging the use of 3D cell cultures.

3D cell culture is one of the rapidly growing segments in the health care space due to considerable range of applications in cancer research, in vitro environment, and regenerative medicine. The ability of 3D cell culture to strengthen the understanding of tissue maturation and organization, organogenesis, and cell differentiation has increased its utility.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=35834

It has also replaced animal prototypes in clinical testing and experiments, as these look similar to cells in vivo. Increase in adoption of 3D cell culture in diagnostic centers, hospitals, and pharmaceutical and biotech companies, and rise in demand in organ transplantation, tissue regeneration, and regenerative medicine. The major drivers of the 3D cell culture market.

Researchers are conducting experiments to advance and develop better options for culturing cells, and 3D cell culturing presents various benefits such as gaining better information and helping to conduct better research. 3D cell structures are relatively thicker. Hence, these could experience some potential barriers. Cells could react and emerge differently in 3D cell culture environment. This would require changes in experiments.

Request for Report Methodology - https://www.transparencymarketresearch.com/sample/sample.php?flag=RRM&rep_id=35834

The global 3D cell culture market can be segmented based on product type, application, end-user, and region. In terms of product type, the market can be divided into scaffold-based 3D cell culture (hydrogels /ECM analogs, micro patterned surfaces, and solid scaffolds), scaffold-free 3D cell culture (low adhesion micro plates, 3D petri dishes, 3D bioreactors, and hanging drop plates), microfluidics-based 3D cell culture, magnetic levitation, and 3D bio printing. Based on application, the global 3D cell culture market can be classified into drug discovery and toxicology, cancer and stem cell research, and tissue engineering & regenerative medicine. In terms of end-user, the market can be categorized into pharmaceutical & biotechnology companies and research laboratories and institutes.

Geographically, the global 3D cell culture market can be segmented into North America, Latin America, Europe, Asia Pacific, and Rest of the world. North America and Europe dominate the market. High market share of these regions is attributed to rise in prevalence of cancer and increase in investment in R&D and health care. Moreover, governments in these regions support advancement in the field of 3D cell culture through grants and funds. The market in Asia Pacific is expected to expand at a high CAGR due to increase in demand for 3D cell culture in developing nations.

Make an Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=35834

Major players in the global 3D cell culture market are Merck, InSphero, Lonza, Thermo Fisher Scientific, Inc., ReproCELL, Inc., Nano3D Biosciences, Inc., Corning Technologies, Synthecon Incorporated, Global Cell Solutions, 3D Boitek, Kuraray Co. Ltd., Hamilton Company, Mimetas, and QGel.

More Trending Reports by Transparency Market Research

Pharmacovigilance Market: The global pharmacovigilance market is expected to reach the value of US$ 11.5 Bn by the end of 2028.

Acute Agitation and Aggression Treatment Market: The acute agitation and aggression treatment market is projected to cross the value of US$ 7.09 Bn by 2031.

Horseradish Peroxidase Market: The global horseradish peroxidase market was valued at ~US$ 49 Mn in 2019 and is anticipated to expand at a CAGR of ~7% from 2020 to 2030.

Companion Animal Diagnostics Market: The clinical biochemistry segment was valued at ~US$ 675 Mn in 2018, is expected to grow at a steady pace during the forecast period to double by the end of 2027.

Back Table and Cart Covers Market: The global back table and cart covers market was valued at ~US$ 720 Mn in 2018, and is projected to reach ~US$ 918 Mn by 2027, expanding at a CAGR of ~3% from 2019 to 2027.

Rheumatoid Arthritis Drugs Market: The global rheumatoid arthritis drugs market was valued at US$ 19597.43 mn in 2016. Taking into consideration the factors associated with the growth of the rheumatoid arthritis drugs market, it is anticipated to expand at a CAGR of 2.96% from 2018 to 2026.

Viral Conjunctivitis Pipeline Drugs Market: The global market for viral conjunctivitis pipeline drugs is likely to exhibit a thumping CAGR of 69.60% between 2020 and 2023 and reach an opportunity worth US$462.4 mn by the end of the forecast period.

Glioma Treatment Market: The global glioma treatment market is estimated to expand at a CAGR of 5.7% during the forecast period 2022 to 2031.

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Website: https://www.transparencymarketresearch.comBlog: https://tmrblog.comEmail: sales@transparencymarketresearch.com

See original here:
3D Cell Culture Market: Rise in Demand in Organ Transplantation, Tissue regeneration, and Regenerative Medicine to Drive the Market - BioSpace

The concept of synthesizing small-scale human organs in lab dishes has matured from pure science fiction to legitimate bioscientific reality in recent years. However, the usefulness of organoids as a research tool for studying the digestive system quickly ran into a roadblock, due to the fact that these in-demand tissues remain difficult to create.

Organoids are stem cell-derived three-dimensional tissue cultures that are designed to exhibit detailed characteristics of organs or act as model organs to produce a specific cell type in laboratory conditions. However, when growing organoids, the yield from each batch of starting material can vary massively and can even fail to produce any viable organoids at all. This of course results in severe delays in their production and utilization in pre-clinical experiments that test the efficacy and safety of drugs.

In a recently published paper from Stem Cell Reports, researchers from Cincinnati childrens (OH, USA) have developed a new practice that overcomes the organoid production hurdle. This novel procedure is already being utilized within the medical facility to boost organoid studies. However, because the materials utilized can be frozen and thawed while still producing high-quality organoids, this discovery allows for the shipment of starter materials to other labs anywhere in the world, foreseeably leading to a dramatic increase in the utilization of human gastrointestinal organoids in medical research.

This method can make organoids a more accessible tool, explains the first author Amy Pitstick, manager of the Pluripotent Stem Cell Facility at Cincinnati Childrens. We show that the aggregation approach consistently produces high yields and we have proven that precursor cells can be thawed from cryogenic storage to produce organoids of the small intestine.

Using this approach will make it possible for many research labs to use organoids in their experiments without the time and expense of learning how to grow induced pluripotent stem cells (iPSCs), states corresponding author Chris Mayhew, director of the Pluripotent Stem Cell Facility. The ability to freeze the precursor cells also will allow labs to easily make organoids without having to start each new experiment with complicated and highly variable iPSC differentiation.

Generally, organoid creation begins with the collection of skin or blood cells, which are then transformed in the lab to become induced pluripotent stem cells. To create intestinal organoids, highly skilled lab professionals produce a flat layer of organ precursor cells known as the mid-hindgut endoderm.

Under the correct conditions, early-stage organoids, termed spheroids, autonomously develop into a three-dimensional ball of cells. These are then collected and placed into a growth medium, which supplies the required signals for the cells to develop into the specialized cell types of a human organ.

However, the quantity of spheroids produced in this manner has been unpredictable. The Cincinnati Childrens researchers discovered that they could harvest the unused precursor cell layer and employ a centrifuge to transport cells into hundreds of tiny wells housed on small plastic plates. This causes the creation of 3D cell aggregates, which may then be collected and utilized to produce organoids.

The experiment described in the research paper demonstrates that the spheroids created in this manner had no discernible differences from those that formed naturally. The scientists then stored samples of the progenitor cells in freezers. These cells generated viable spheroids after being frozen and aggregated.

The paper goes on to verify that these spheroids can be consistently grown into mature organoids, which can simulate organ function. In the case of this research, the mature organoids went on to mimic the function of the small intestine, large intestine and the antrum, the portion of the stomach that links to the intestine.

Although this development is a welcome and promising advance in organoid fabrication, years of research will be required to create organoids large enough and complex enough to be utilized as replacement tissue in transplant surgery. However, having access to a large number of readily manufactured organoids offers up numerous possibilities for medical study.

More labs will be able to create patient-specific organoids in order to evaluate drugcombination therapiesfor precision treatment of complex or rare disease states that necessitate personalized care. Scientists also conducting basic research to understand more about the genetic factors and molecular pathways at play in digestive tract diseases will be able to incorporate organoids in their experiments by procuring frozen spheroid precursors.

In his current effort to generate transplantable intestinal tissues, Michael Helmrath, Director of Clinical Translation for the Center for Stem Cell & Organoid Medicine (CuSTOM) at Cincinnati Childrens, has already begun employing materials made from this new method.

This is a great step forward for the field on many fronts, Helmrath says. To be able to reduce the complexity of the process and provide higher yields is beneficial to our work. And to be able to translate the methods to other labs will help move regenerative medicine forward.

Source: https://linkinghub.elsevier.com/retrieve/pii/S2213671122003599

Go here to see the original:
New milestone organoid synthesis will boost disease and drug development research - RegMedNet

CAMBRIDGE, Mass., Aug. 4, 2022 /PRNewswire/ --Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming platform, today announced financial results for the second quarter ended June 30, 2022, and highlighted recent Company progress.

"This has been an exciting second quarter for Omega, in which we were thrilled to receive FDA clearance of our first IND application for OTX-2002, representing the first ever Omega Epigenomic ControllerTM, a new class of programmable mRNA therapeutics. This is a critical milestone for Omega as we enter our next phase of growth and reflects our pioneering work to realizethe potential ofepigenomic programming," said Mahesh Karande, President and Chief Executive Officer of Omega Therapeutics. "Additionally, we were also pleased to share exciting, new supportive preclinical data, both from our lead program OTX-2002 in hepatocellular carcinoma, as well as from another program in our pipeline focused on non-small cell lung cancer, a potential future indication. We look forward to continuing this momentum as we enter the clinic in the second half of this year and further exploring the broad ranging capabilities of our novel platform in additional therapeutic areas."

Recent Business Highlights

Development Pipeline and Platform

Corporate

Second Quarter 2022 Financial Results

As of June 30, 2022, the Company had cash, cash equivalents and marketable securities totaling $173.7 million.

Research and development (R&D) expenses for the second quarter of 2022 were $19.4 million, compared to $11.2 million for the second quarter of 2021. The $8.2 million increase in R&D expense was primarily driven by an increase in personnel-related expenses, external manufacturing costs, and study costs in support of the advancement of our programs

General and administrative (G&A) expenses for the second quarter of 2022 were $6.2 million, compared to $3.6 million for the second quarter of 2021. The $2.6 million increase in G&A expense was primarily driven by an increase in personnel-related expenses to support business growth.

Net loss for the second quarter of 2022 was $25.9 million, compared to $15.4 million for the second quarter of 2021, driven predominantly by increased R&D and G&A expenses to support the Company's growth and operations as a public company.

About Omega Therapeutics

Omega Therapeutics, founded by Flagship Pioneering, is a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines. The company's OMEGA Epigenomic Programming platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism's life from cell genesis, growth, and differentiation to cell death. Using a suite of technologies, paired with Omega's process of systematic, rational, and integrative drug design, the OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega's modular and programmable mRNA medicines, Omega Epigenomic Controllers, are designed to target specific epigenomic loci within insulated genomic domains, EpiZips, from amongst thousands of unique, mapped, and validated genome-wide DNA-sequences, with high specificity to durably tune single or multiple genes to treat and cure diseases through Precision Genomic Control. Omega is currently advancing a broad pipeline of development candidates spanning a range of disease areas, including oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases, including alopecia.

For more information, visitomegatherapeutics.com, or follow us onTwitterandLinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the timing and design of our Phase 1/2 MYCHELANGELOTM clinical trial; the potential of the OMEGA platform to engineer programmable epigenetic mRNA therapeutics that successfully regulate gene expression by targeting insulated genomic domains; expectations surrounding the potential of our product candidates, including our lead OEC candidate OTX-2002; and expectations regarding our pipeline, including trial design, initiation of preclinical studies and advancement of multiple preclinical development programs in oncology, immunology, regenerative medicine, and select monogenic diseases. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the novel technology on which our product candidates are based makes it difficult to predict the time and cost of preclinical and clinical development and subsequently obtaining regulatory approval, if at all; the substantial development and regulatory risks associated with epigenomic controller machines due to the novel and unprecedented nature of this new category of medicines; our limited operating history; the incurrence of significant losses and the fact that we expect to continue to incur significant additional losses for the foreseeable future; our need for substantial additional financing; our investments in research and development efforts that further enhance the OMEGA platform, and their impact on our results; uncertainty regarding preclinical development, especially for a new class of medicines such as epigenomic controllers; potential delays in and unforeseen costs arising from our clinical trials; the fact that our product candidates may be associated with serious adverse events, undesirable side effects or have other properties that could halt their regulatory development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences; the impact of increased demand for the manufacture of mRNA and LNP based vaccines to treat COVID-19 on our development plans; difficulties manufacturing the novel technology on which our OEC candidates are based; our ability to adapt to rapid and significant technological change; our reliance on third parties for the manufacture of materials; our ability to successfully acquire and establish our own manufacturing facilities and infrastructure; our reliance on a limited number of suppliers for lipid excipients used in our product candidates; our ability to advance our product candidates to clinical development; and our ability to obtain, maintain, enforce and adequately protect our intellectual property rights. These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Investor contact: Kevin MurphyArgot Partners212.600.1902[emailprotected]

Media contact: Jason Braco, Ph.D.LifeSci Communications646.751.4361[emailprotected]

Omega Therapeutics, Inc.

Condensed consolidated statements of operations and comprehensive loss

(thousands, except share and per share amounts)

Three Months Ended June30,

Six Months Ended June30,

2022

2021

2022

2021

Collaboration revenue from related party

$

476

$

$

743

$

Operating expenses:

Research and development

19,387

11,184

33,659

20,933

General and administrative

6,202

3,637

11,336

6,452

Related party expense, net

741

384

1,562

763

Total operating expenses

26,330

15,205

46,557

28,148

Loss from operations

(25,854)

(15,205)

(45,814)

(28,148)

Other expense, net:

Interest expense, net

(55)

(190)

(210)

(402)

Change in fair value of warrant liability

(11)

(340)

Other expense, net

(3)

(4)

(52)

(8)

Total other expense, net

(58)

(205)

(262)

(750)

Net loss

$

(25,912)

$

(15,410)

$

(46,076)

$

(28,898)

Net loss per common stock attributable to common

stockholders, basic and diluted

$

(0.54)

$

(3.36)

$

(0.96)

$

Continue reading here:
Omega Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress - PR Newswire

Record revenue of $64.2 million for the quarter, up 14% as reported and 18% at constant currency (year-over-year)

Supporting a record 626 global clinical trials; a net of 17 new trials added during the quarter

Opened first two Global Supply Chain Centers, which include BioServices, in June 2022

Expanded global footprint into Spain and Ireland

NASHVILLE, Tenn., Aug. 4, 2022 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced financial results for the three- and six-month periods ended June 30,2022.

Cryoport, Inc.

Jerrell Shelton, CEO of Cryoport, commented, "We delivered a strong performance for the second quarter of 2022 highlighted by overall top-line growth of 14%, or 18% on a constant currency basis. Each of our end markets, Biopharma/Pharma, Reproductive Medicine and Animal Health, grew in the double digits during the quarter driven by strong continued demand for all of our products and services.

"Our Biopharma/Pharma revenue was $51.7 million for the second quarter of 2022 compared to $45.5 million for the second quarter of 2021. We are now supporting a record 626 global clinical trials in regenerative medicine, up by 17 trials sequentially compared to our previous quarter end. Importantly our clinical trial pipeline continues to mature with 285 trials now in Phase 2 and 81 in Phase 3. Overall revenue growth in the Biopharma/Pharma market was driven by our support of global clinical trials and commercially launched therapies.

"Demand for our Animal Health products and services, which is driven primarily by protein production, increased by 14% to $9.6 million for the second quarter of 2022.

"Reproductive Medicine revenue increased by 24% to $2.9 million for the second quarter of 2022. This growth was driven by CryoStork logistics solutions and cryogenic shipper products. We continued to grow in the Reproductive Medicine market as the number of fertility clinics we support increases and as IVF technologies continue to stimulate increased interest on a global basis.

Story continues

"Our strategic expansion continued to progress during the second quarter and included the grand openings of Cryoport's two new Global Supply Chain Centers in Texas and New Jersey. These world-class facilities form the foundation of our Global Supply Chain Center Network and include the important addition of GMP (Good Manufacturing Practices) BioServices to our portfolio of premier, comprehensive supply chain solutions. During the quarter, we further strengthened our presence in the EMEA region with the acquisition of Cell&Co BioServices in Clermont-Ferrand, France. We anticipate that Cell&Co BioServices will play a significant role in the further development of our Global Supply Chain Center Network as we expand into the Paris, France region.

"We also continued our development in EMEA subsequent to quarter end with CRYOPDP opening a logistics center in Ireland and acquiring Polar Expres, based in Spain, which adds logistics centers in Madrid and Barcelona. Additionally, Cryoport Systems just completed the acquisition of Cell Matters, based in Belgium, specializing in cryo-process optimization, cryo-processing, and cryopreservation. These developments are important steps in further building out our leadership position as a provider of global temperature-controlled supply chain solutions to the life sciences industry and are expected to also positively impact our operations in the Americas and APAC in the future.

Mr. Shelton concluded, "We continue to have robust product and services development projects underway as well as an accretive acquisition pipeline. We remain confident in our outlook for the remainder of the year and reiterate our previous full year 2022 revenue guidance to be between $260 million and $265 million, representing a 17% to 19% increase over 2021 revenue."

In tabular form, revenue by market for the three- and six-month periods ended June 30, 2022, as compared to the same period in 2021 was asfollows:

Cryoport, Inc. and Subsidiaries

Total revenues by market

(unaudited)

Three Months Ended June 30,

Six Months Ended June 30,

(in thousands)

2022

2021

% Change

2022

2021

% Change

Biopharma/Pharma

$ 51,728

$ 45,489

14%

$ 94,739

$ 87,877

8%

Animal Health

9,562

8,394

14%

16,356

17,394

-6%

Reproductive Medicine

2,863

2,308

24%

5,360

4,204

28%

Total revenues

$ 64,153

$ 56,191

14%

$ 116,455

$ 109,475

6%

As of June 30, 2022, the Company supportednine (9) commercial therapies and anettotalof 626 global clinical trials, a net increase of 65 clinical trials over second quarter 2021 and an increase of 24 clinical trials from year-end 2021. The number of trials in Phase 3 was 81 as of the end of the second quarter. The number of trials by phase and region are as follows:

Cryoport Supported Clinical Trials by Phase

Clinical Trials

June 30,

2020

2021

2022

Phase 1

198

227

260

Phase 2

227

265

285

Phase 3

66

69

81

Total

491

561

626

Cryoport Supported Clinical Trials by Region

Clinical Trials

June 30,

2020

2021

2022

Americas

400

444

488

EMEA

72

88

104

APAC

19

29

34

Total

491

561

626

Continue reading here:
Cryoport Reports Results for the Second Quarter 2022 - Yahoo Finance

CAMBRIDGE, Mass., Aug. 3, 2022 /PRNewswire/ --Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing platform, today announced that Thomas McCauley, Chief Scientific Officer, will participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Conference on August 10, 2022, at 8 a.m. ET.

A live webcast of the fireside chat will be available on the Investors & Media section of the Company's website at http://www.omegatherapeutics.com. An archived replay of the fireside chat will be available on the same website for approximately 90 days.

About Omega Therapeutics

Omega Therapeutics, founded by Flagship Pioneering, is a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines. The company's OMEGA Epigenomic Programming platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism's life from cell genesis, growth, and differentiation to cell death. Using a suite of technologies, paired with Omega's process of systematic, rational, and integrative drug design, the OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega's modular and programmable mRNA medicines, Omega Epigenomic Controllers, target specific epigenomic loci within insulated genomic domains, EpiZips, from amongst thousands of unique, mapped, and validated genome-wide DNA-sequences, with high specificity to durably tune single or multiple genes to treat and cure diseases through Precision Genomic Control. Omega is currently advancing a broad pipeline of development candidates spanning a range of disease areas, including oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases, including alopecia.

For more information, visitomegatherapeutics.com, or follow us onTwitterandLinkedIn.

Contacts

Media contact:Jason BracoLifeSci Communications646.751.4361jbraco@lifescicomms.com

Investor contact:Kevin MurphyArgot Partners212.600.1902ArgotOmega@argotpartners.com

(PRNewsfoto/Omega Therapeutics)

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/omega-therapeutics-to-participate-in-the-2022-wedbush-pacgrow-healthcare-conference-301598098.html

SOURCE Omega Therapeutics

The rest is here:
Omega Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Conference - Yahoo Finance